WPRIM Management System> DCMS> Clinical and Molecular Hepatology> 2021> 27> 2

Volume: 27 Issue: 2

1. Clinical and serological prognostic markers in primary biliary cholangitis Page:360—361
2. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Page:257—269
3. Another oral antiviral treatment, but still far away from hepatitis B virus cure Page:281—282
4. Biopsy or cytology for diagnosing hepatic focal lesions? Page:278—280
5. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact Page:273—277
6. A need for patient-centered care in managing patients with liver cirrhosis Page:270—272
7. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial Page:346—359
8. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis Page:329—345
9. Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma Page:313—328
10. Direct comparison of biopsy techniques for hepatic malignancies Page:305—312
11. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B Page:295—304
12. Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study Page:283—294
13. Current and future strategies for the treatment of chronic hepatitis C Page:246—256
14. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects Page:236—245
15. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease Page:221—235
16. Clinical and serological prognostic markers in primary biliary cholangitis Page:360—361
17. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple? Page:257—269
18. Another oral antiviral treatment, but still far away from hepatitis B virus cure Page:281—282
19. Biopsy or cytology for diagnosing hepatic focal lesions? Page:278—280
20. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact Page:273—277
21. A need for patient-centered care in managing patients with liver cirrhosis Page:270—272
22. Continuing besifovir dipivoxil maleate versus switching from tenofovir disoproxil fumarate for treatment of chronic hepatitis B: Results of 192-week phase 3 trial Page:346—359
23. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis Page:329—345
24. Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognos- tic factor in hepatitis C virus-related hepatocellular carcinoma Page:313—328
25. Direct comparison of biopsy techniques for hepatic malignancies Page:305—312
26. Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B Page:295—304
27. Association between new-onset liver cirrhosis and suicide risk in South Korea: A nationwide cohort study Page:283—294
28. Current and future strategies for the treatment of chronic hepatitis C Page:246—256
29. Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects Page:236—245
30. Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease Page:221—235

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.